REDWOOD CITY, Calif., May 21 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from three studies at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2009, at the Orange County Convention Center in Orlando, Florida. The company currently markets the widely-adopted Oncotype DX(R) breast cancer test, which is clinically validated to predict the likelihood of recurrence and chemotherapy benefit in early-stage breast cancer patients, and plans to launch a test for colon cancer in early 2010 based on positive results from the QUASAR validation study being presented at ASCO.
Presentation details are as follows: Colon Cancer -- Saturday, May 30, 2009, 3 p.m. ET Abstract # 4000 Oral presentation: "A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study" Presenter: David Kerr, M.D., DSc, professor of cancer medicine at the University of Oxford Location: Level 2, West Hall D2 In addition, an archived webcast of the advance presscast highlighting the QUASAR colon cancer validation study is available on ASCO's Web site at www.asco.org. Breast Cancer -- Sunday, May 31, 2009, 4:30 p.m. ET Abstract # 500 Oral presentation: "Genotypic characterization of phenotypically defined triple-negative breast cancer" Presenter: Joseph A. Sparano, M.D., professor of medicine and women's health at Albert Einstein College of Medicine and director of the Breast Evaluation Center of Montefiore-Einstein Cancer Center in the Bronx, New York Location: Level 2, West Hall D2 -- Monday, June 1, 2009, 1-5:00 p.m. ET Abstract # 549 Poster presentation: "Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers" Presenter: Steve Shak, M.D., chief medical officer, Genomic Health Poster board: A17 Location: Level 2, West Hall C
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes and the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
|SOURCE Genomic Health|
Copyright©2009 PR Newswire.
All rights reserved